Vivalyx
PrivateLast Round
VC Round
Feb 19, 2025
Total Funding Raised
$10.02M
Company Overview
Vivalyx is a biotech company that has developed a patented, blood-free preservation liquid called Omnisol for organ preservation before transplantation.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivalyx Comparables
Compare Vivalyx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Carnamedica Sp. z o.o. | 83% | |
| Dr. Franz Köhler Chemie GmbH | 81% | |
| Bridge to Life | 79% |
Vivalyx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Feb 19, 2025 | ||||
| Grant | Feb 19, 2025 | ||||
| Seed | Apr 30, 2024 | ||||
| Pre Seed | Jun 15, 2023 |
Key People
Founding team and executive leadership
Vivalyx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant, VC Round |
| Tech Vision Fonds | Grant, Seed |
| Arve Capital | Grant, Seed |
| GOOSE Capital | Grant, Seed |
| Brightlands Venture Partners | Grant, Seed |
| Angel Invest | Grant, Pre Seed, Seed |
| Angel Invest | Pre Seed, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2026
Hiring Head of Production for Omnisol's European launch.
- Feb 19, 2025
Secured $2.69M in grant funding.
Vivalyx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access